Nifty
Sensex
:
:
11354.25
37808.91
-102.65 (-0.90%)
-355.70 (-0.93%)

Pharmaceuticals & Drugs

Rating :
44/99

BSE: 532531 | NSE: STAR

436.70
-5.45 (-1.23%)
25-Mar-2019 | 3:55PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  439.85
  •  441.35
  •  434.45
  •  442.15
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  564801
  •  2466.49
  •  718.50
  •  333.30

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 3,909.28
  • 4.64
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 6,125.92
  • 0.46%
  • 1.63

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 30.79%
  • 0.00%
  • 14.11%
  • FII
  • DII
  • Others
  • 0.41%
  • 24.53%
  • 30.16%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 20.01
  • 5.27

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 9.44
  • -1.62

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 67.81
  • 81.53

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 8.65
  • 22.34
  • 23.87

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.06
  • 3.66
  • 2.68

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 22.29
  • 20.72
  • 15.98

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 18
Dec 17
Var%
Sep 18
Sep 17
Var%
Jun 18
Jun 17
Var%
Mar 18
Mar 17
Var%
Net Sales
794.50
748.79
6.10%
732.63
768.66
-4.69%
663.46
657.78
0.86%
664.15
677.13
-1.92%
Expenses
667.41
617.83
8.02%
633.03
660.88
-4.21%
582.68
586.52
-0.65%
577.63
547.52
5.50%
EBITDA
127.09
130.96
-2.96%
99.60
107.78
-7.59%
80.78
71.26
13.36%
86.52
129.61
-33.25%
EBIDTM
16.00%
17.49%
13.59%
14.02%
12.18%
10.83%
13.03%
19.14%
Other Income
0.83
15.66
-94.70%
7.73
22.14
-65.09%
10.64
34.46
-69.12%
21.80
62.39
-65.06%
Interest
50.09
49.77
0.64%
48.48
48.58
-0.21%
44.12
52.42
-15.83%
45.47
47.87
-5.01%
Depreciation
40.67
37.95
7.17%
44.49
37.25
19.44%
42.87
34.49
24.30%
44.34
37.69
17.64%
PBT
37.90
52.58
-27.92%
6.97
31.84
-78.11%
-0.51
15.45
-
-3.14
98.81
-
Tax
6.33
2.01
214.93%
1.61
5.42
-70.30%
-4.27
4.24
-
-3.95
7.91
-
PAT
31.57
50.57
-37.57%
5.36
26.42
-79.71%
3.76
11.21
-66.46%
0.81
90.90
-99.11%
PATM
3.97%
6.75%
0.73%
3.44%
0.57%
1.70%
0.12%
13.42%
EPS
32.77
9.56
242.78%
-1.34
0.96
-
-0.66
0.06
-
63.54
12.57
405.49%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Dec 12
Dec 11
Dec 10
Dec 09
Dec 08
Net Sales
2,854.74
3,338.63
3,826.22
2,862.19
1,195.85
1,340.96
961.76
2,550.04
1,695.84
1,304.77
1,020.33
Net Sales Growth
0.08%
-12.74%
33.68%
139.34%
-10.82%
39.43%
-62.28%
50.37%
29.97%
27.88%
 
Cost Of Goods Sold
1,368.20
1,378.84
1,281.17
1,502.29
560.49
714.67
491.82
1,264.39
805.65
700.90
524.20
Gross Profit
1,486.54
1,959.80
2,545.05
1,359.90
635.37
626.30
469.94
1,285.66
890.19
603.86
496.13
GP Margin
52.07%
58.70%
66.52%
47.51%
53.13%
46.71%
48.86%
50.42%
52.49%
46.28%
48.62%
Total Expenditure
2,460.75
2,987.89
3,309.30
2,481.62
967.00
1,117.54
861.18
2,059.36
1,369.22
1,117.84
950.87
Power & Fuel Cost
-
51.33
33.87
77.18
16.02
18.56
12.84
54.24
30.23
24.58
30.81
% Of Sales
-
1.54%
0.89%
2.70%
1.34%
1.38%
1.34%
2.13%
1.78%
1.88%
3.02%
Employee Cost
-
434.05
419.16
357.69
172.06
157.18
120.30
302.74
219.57
177.01
176.81
% Of Sales
-
13.00%
10.95%
12.50%
14.39%
11.72%
12.51%
11.87%
12.95%
13.57%
17.33%
Manufacturing Exp.
-
115.97
137.47
119.23
41.37
35.76
44.43
89.60
63.83
45.15
48.93
% Of Sales
-
3.47%
3.59%
4.17%
3.46%
2.67%
4.62%
3.51%
3.76%
3.46%
4.80%
General & Admin Exp.
-
194.38
172.63
198.71
86.25
66.37
58.16
182.12
159.16
86.87
80.59
% Of Sales
-
5.82%
4.51%
6.94%
7.21%
4.95%
6.05%
7.14%
9.39%
6.66%
7.90%
Selling & Distn. Exp.
-
208.85
161.12
129.57
61.37
66.67
39.94
116.07
88.02
73.40
71.81
% Of Sales
-
6.26%
4.21%
4.53%
5.13%
4.97%
4.15%
4.55%
5.19%
5.63%
7.04%
Miscellaneous Exp.
-
604.48
1,103.88
96.95
29.44
58.33
93.69
50.21
2.76
9.92
71.81
% Of Sales
-
18.11%
28.85%
3.39%
2.46%
4.35%
9.74%
1.97%
0.16%
0.76%
1.74%
EBITDA
393.99
350.74
516.92
380.57
228.85
223.42
100.58
490.68
326.62
186.93
69.46
EBITDA Margin
13.80%
10.51%
13.51%
13.30%
19.14%
16.66%
10.46%
19.24%
19.26%
14.33%
6.81%
Other Income
41.00
805.61
398.08
102.37
38.57
60.23
34.20
31.67
69.70
23.57
310.92
Interest
188.16
196.24
183.10
168.17
47.44
108.88
79.45
194.83
146.65
75.91
84.70
Depreciation
172.37
193.93
198.69
131.25
64.03
56.48
30.86
104.30
63.90
49.19
39.90
PBT
41.22
766.17
533.20
183.50
155.95
118.30
24.48
223.22
185.77
85.41
255.78
Tax
-0.28
25.46
51.19
42.45
147.60
40.86
11.15
38.68
45.19
21.90
10.79
Tax Rate
-0.68%
3.52%
10.30%
29.87%
99.35%
44.53%
1.54%
14.18%
24.25%
15.32%
9.39%
PAT
41.50
677.27
399.38
113.21
1.57
50.89
712.39
224.48
122.45
109.68
107.96
PAT before Minority Interest
24.55
697.14
445.58
99.68
0.98
50.89
713.44
234.01
141.18
121.04
104.08
Minority Interest
-16.95
-19.87
-46.20
13.53
0.59
0.00
-1.05
-9.53
-18.73
-11.36
3.88
PAT Margin
1.45%
20.29%
10.44%
3.96%
0.13%
3.80%
74.07%
8.80%
7.22%
8.41%
10.58%
PAT Growth
-76.83%
69.58%
252.78%
7,110.83%
-96.91%
-92.86%
217.35%
83.32%
11.64%
1.59%
 
Unadjusted EPS
94.31
73.81
44.73
13.14
141.85
298.56
121.47
38.65
26.11
26.49
26.91

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Dec 12
Dec 11
Dec 10
Dec 09
Dec 08
Shareholder's Funds
2,454.56
2,748.82
2,657.87
1,144.92
1,006.83
2,026.24
1,371.48
1,282.78
831.07
415.41
Share Capital
89.50
89.42
89.35
59.62
59.57
58.80
58.38
57.74
89.38
89.21
Total Reserves
2,356.00
2,650.55
2,562.75
1,084.50
947.06
1,963.94
1,310.34
1,222.95
724.09
324.41
Non-Current Liabilities
1,908.40
2,048.67
2,760.03
285.79
306.42
900.59
1,132.57
2,012.89
1,459.17
1,306.42
Secured Loans
1,551.09
1,622.87
2,614.88
250.23
274.29
731.15
1,054.31
1,387.39
778.70
566.01
Unsecured Loans
0.23
14.84
12.13
17.16
1.24
0.00
0.00
622.45
678.17
736.00
Long Term Provisions
16.55
25.19
14.45
6.02
16.56
57.25
66.19
0.00
0.00
0.00
Current Liabilities
1,899.30
3,103.87
1,891.98
1,019.94
707.37
1,797.29
2,791.73
923.65
684.15
420.98
Trade Payables
712.07
774.09
775.40
234.41
262.31
463.08
585.04
419.85
445.23
335.64
Other Current Liabilities
129.98
819.08
347.93
502.47
127.27
651.65
1,369.80
305.00
64.64
24.28
Short Term Borrowings
944.39
1,393.96
700.48
203.03
224.56
599.89
684.65
0.00
0.00
0.00
Short Term Provisions
112.86
116.73
68.19
80.03
93.23
82.66
152.24
198.80
174.28
61.06
Total Liabilities
6,416.91
8,034.86
7,360.09
2,469.36
2,096.29
4,795.97
5,342.24
4,491.79
3,232.89
2,323.09
Net Block
2,735.01
2,909.03
2,678.68
701.36
554.53
3,016.72
3,187.64
2,328.27
1,856.59
969.52
Gross Block
3,028.73
3,186.12
2,825.43
1,080.55
907.33
3,514.29
3,644.82
2,626.71
2,080.70
1,189.65
Accumulated Depreciation
293.71
277.09
146.75
379.19
352.80
497.57
457.19
298.44
224.11
220.12
Non Current Assets
3,933.32
4,243.05
3,845.20
1,039.91
787.65
3,383.87
3,711.33
2,521.48
2,282.61
1,575.48
Capital Work in Progress
620.29
780.18
814.88
171.17
99.47
241.44
285.03
191.46
84.66
259.55
Non Current Investment
350.08
315.66
127.19
68.76
41.80
0.00
0.00
1.76
341.36
346.40
Long Term Loans & Adv.
199.64
222.56
201.83
96.72
90.40
118.75
229.99
0.00
0.00
0.00
Other Non Current Assets
28.30
15.62
22.62
1.91
1.45
6.96
8.67
0.00
0.00
0.00
Current Assets
2,483.59
3,791.82
3,514.89
1,429.44
1,308.63
1,410.94
1,625.27
1,960.40
950.29
747.52
Current Investments
311.48
1,279.54
1,213.76
561.29
401.24
0.06
0.00
0.00
0.00
0.00
Inventories
552.02
732.80
613.14
207.68
175.99
442.33
479.93
312.00
233.42
173.12
Sundry Debtors
882.18
995.91
1,032.97
389.96
364.00
483.23
538.44
383.78
420.27
337.51
Cash & Bank
303.33
329.48
311.59
146.88
231.15
165.74
259.73
339.45
91.20
56.95
Other Current Assets
434.59
209.70
245.90
69.18
136.26
319.58
347.17
925.17
205.40
179.94
Short Term Loans & Adv.
295.75
244.39
97.54
54.46
79.06
44.38
91.79
850.18
150.94
99.87
Net Current Assets
584.29
687.95
1,622.91
409.50
601.26
-386.35
-1,166.46
1,036.75
266.14
326.54
Total Assets
6,416.91
8,034.87
7,360.09
2,469.35
2,096.28
4,795.98
5,342.23
4,491.80
3,232.90
2,323.10

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Dec 12
Dec 11
Dec 10
Dec 09
Dec 08
Cash From Operating Activity
187.07
288.14
73.25
83.40
-271.68
134.26
457.10
323.93
89.61
117.75
PBT
705.80
497.14
146.44
992.01
2,889.87
949.49
272.69
186.37
142.94
114.88
Adjustment
-274.51
190.92
345.56
-756.73
-2,775.01
-415.93
113.84
178.94
42.76
19.47
Changes in Working Capital
-190.66
-341.30
-341.71
-95.91
-260.68
-310.56
128.87
-2.09
-82.37
-6.80
Cash after chg. in Working capital
240.63
346.76
150.29
139.37
-145.81
223.00
515.40
363.23
103.33
127.54
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-53.56
-58.62
-77.04
-55.97
-125.87
-88.75
-58.30
-39.29
-13.72
-9.80
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
582.59
-686.69
-2,224.83
51.87
4,077.09
806.54
-656.47
-941.00
-147.64
-218.93
Net Fixed Assets
709.54
-236.66
-535.93
-66.57
-119.10
-38.27
-18.46
-42.91
-26.86
-108.24
Net Investments
747.64
-143.27
-1,478.58
78.09
248.81
-508.54
77.70
653.52
-578.46
-103.41
Others
-874.59
-306.76
-210.32
40.35
3,947.38
1,353.35
-715.71
-1,551.61
457.68
-7.28
Cash from Financing Activity
-1,015.69
338.21
2,943.94
-421.25
-3,318.53
-990.03
89.36
850.09
91.64
13.43
Net Cash Inflow / Outflow
-246.03
-60.33
792.35
-285.98
486.88
-49.23
-110.01
233.03
33.60
-87.75
Opening Cash & Equivalents
515.08
1,110.74
298.91
586.00
132.02
211.93
325.17
79.00
45.88
179.34
Closing Cash & Equivalent
256.16
515.08
1,110.74
298.42
586.00
132.02
212.27
325.17
78.78
45.88

Financial Ratios

Consolidated /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Dec 12
Dec 11
Dec 10
Dec 09
Dec 08
Book Value (Rs.)
273.24
306.41
296.83
191.91
168.99
343.78
233.49
220.07
190.06
90.98
ROA
9.65%
5.79%
2.03%
0.04%
1.48%
14.07%
4.76%
3.66%
4.36%
4.78%
ROE
26.89%
16.53%
5.25%
0.09%
3.36%
42.16%
17.77%
13.87%
21.45%
36.41%
ROCE
16.09%
10.75%
7.54%
10.92%
7.76%
21.08%
12.82%
11.96%
10.93%
12.20%
Fixed Asset Turnover
1.07
1.27
1.47
1.21
0.61
0.27
0.82
0.72
0.80
0.87
Receivable days
102.66
96.77
90.73
114.71
114.80
193.43
65.68
86.42
105.79
97.90
Inventory Days
70.23
64.20
52.34
58.37
83.78
174.61
56.40
58.62
56.75
66.94
Payable days
116.23
117.33
75.51
76.81
112.69
253.28
92.58
119.83
129.46
131.06
Cash Conversion Cycle
56.67
43.64
67.55
96.27
85.89
114.76
29.50
25.22
33.08
33.78
Total Debt/Equity
1.03
1.35
1.34
0.78
0.54
0.79
1.94
1.58
1.79
3.15
Interest Cover
4.68
3.71
1.85
4.13
1.84
10.12
2.40
2.27
2.88
2.36

News Update:


  • Strides Pharma Science’s arm gets USFDA’s nod for Ethosuximide Softgel Capsules
    20th Feb 2019, 11:38 AM

    The product will be manufactured at flagship facility in Bangalore and will be marketed by Strides Pharma Inc. in the US market

    Read More
  • Strides Pharma Science’s arm receives approval for Triamcinolone Acetonide Cream
    13th Feb 2019, 09:16 AM

    The product is a generic version of Triamcinolone Acetonide Cream of Mylan Pharmaceuticals Inc.

    Read More
  • Strides Pharma Science gets EIR from USFDA for formulations facility in Bangalore
    6th Feb 2019, 09:07 AM

    The inspection conducted in November 2018 had concluded with Zero 483 observations

    Read More
  • Strides Pharma Science's arm to exit investment in Arrow
    30th Jan 2019, 09:25 AM

    The initial net proceeds of AUD 300 million along with additional $42 million released from the general claims escrow account on Agila transaction

    Read More
  • Strides Pharma Science to convert 50:50 JV with Vivimed to 100% ownership
    30th Jan 2019, 09:05 AM

    Consequently, Strides will acquire balance 50% stake in Vivimed Life Sciences

    Read More
  • Strides Pharma’s arm to acquire 80% stake in Pharmapar
    29th Jan 2019, 14:14 PM

    The company to fast track growth in the region through rapid portfolio expansion driven by its fungible portfolio built in the markets of US, Europe and Australia

    Read More
  • Strides Pharma Scien - Quarterly Results
    29th Jan 2019, 12:46 PM

    Read More
  • Strides Pharma completes investment in Strides Consumer Healthcare Business
    24th Dec 2018, 12:14 PM

    India Life Sciences Fund III advised by ICP-III Investment Advisors has partnered with Strides

    Read More
  • Strides Pharma’s arm gets USFDA’s approval for Polyethylene Glycol, Electrolytes
    24th Dec 2018, 09:21 AM

    The company has 80 cumulative ANDA filings with USFDA of which 55 ANDAs have been approved including 11 approvals received in FY 19

    Read More
  • Strides to receive $42 million immediately from General Claims Escrow
    19th Dec 2018, 10:53 AM

    The claims in that arbitration were rejected in their entirety

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.